The US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) have released a joint statement recommending a pause in the use of the Johnson & Johnson Covid-19 vaccine. Both agencies are currently reviewing data involving six US cases of unusual blood clots among the 6.8 million shots administered in the country. The company is also reviewing these cases with health authorities in Europe, after delaying the rollout of the vaccine on the continent and pausing vaccinations in all Janssen Covid-19 vaccine clinical trials. The news follows the ongoing investigations into links between the AstraZeneca Covid-19 vaccine and rare blood clotting events.
Moderna has provided clinical and supply updates on its Covid-19 vaccine programme. New results from a preclinical study of the company’s Covid-19 variant-specific vaccine candidates showed that its variant-specific booster vaccine candidates (mRNA-1273.351 and mRNA-1273.211) increase neutralising titres against SARS-CoV-2 variants of concern. The company has delivered approximately 132 million doses of its Covid-19 vaccine globally.